Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,504 active trials253 approved drugs3,568 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,622 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03654547 | Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer | completed | Phase 1 | 48 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 2 | Jul 24, 2025 | clinicaltrials |
| NCT04813653 | Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells | completed | Phase 1 | 3 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jul 24, 2025 |
| clinicaltrials |
| NCT05506982 | Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain | completed | Phase 1 | 11 | Emory UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05544227 | Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 15 | Williams Cancer FoundationOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04381832 | Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 173 | Arcus Biosciences, Inc.INDUSTRY | 2 | Jul 22, 2025 | clinicaltrials |
| NCT06886659 | A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche) | completed | Phase 1 | 80 | Incepta Pharmaceuticals LtdINDUSTRY | 1 | Jul 22, 2025 | clinicaltrials |
| NCT03199586 | Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies | completed | Phase 1 | 23 | Novita Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT04473911 | Haplo Peripheral Blood Sct In GVHD Prevention | completed | Phase 1 | 25 | Zachariah Michael DeFilippOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT05011097 | A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 20 | Wuhan YZY Biopharma Co., Ltd.INDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT05444530 | A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms | completed | Phase 1 | 14 | Janssen Research & Development, LLCINDUSTRY | 2 | Jul 20, 2025 | clinicaltrials |
| NCT01342354 | Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer | completed | Phase 1 / Phase 2 | 15 | University of ChicagoOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT02956382 | Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma | completed | Phase 1 / Phase 2 | 24 | Georgetown UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT03617003 | Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11) | completed | Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT01051635 | A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Jul 17, 2025 | clinicaltrials |
| NCT04247282 | Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection | completed | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2025 | clinicaltrials |
| NCT02204072 | BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) | completed | Phase 1 | 120 | Boehringer IngelheimINDUSTRY | 8 | Jul 15, 2025 | clinicaltrials |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | Incyte CorporationINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT04826003 | Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment | completed | Phase 1 | 54 | Hoffmann-La RocheINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT03131037 | Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer | completed | Phase 1 | 12 | Candel Therapeutics, Inc.INDUSTRY | 1 | Jul 11, 2025 | clinicaltrials |
| NCT04580485 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | completed | Phase 1 | 54 | Incyte CorporationINDUSTRY | 6 | Jul 11, 2025 | clinicaltrials |
| NCT02836548 | HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma | completed | Phase 1 / Phase 2 | 33 | The Netherlands Cancer InstituteOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT05169944 | Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors(PNOC025) | completed | Phase 1 | 13 | University of California, San FranciscoOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT02039336 | Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC(M13DAP) | completed | Phase 1 / Phase 2 | 35 | The Netherlands Cancer InstituteOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT02230553 | Lapatinib Plus Trametinib in KRAS Mutant NSCLC(M14LTK) | completed | Phase 1 / Phase 2 | 35 | The Netherlands Cancer InstituteOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT03128047 | HUMC 1612: Optune NovoTTF-200A System | completed | Phase 1 | 7 | Hackensack Meridian HealthOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT00703222 | A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells(CHESAT) | completed | Phase 1 / Phase 2 | 7 | Baylor College of MedicineOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT01628640 | Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors | completed | Phase 1 | 17 | Mayo ClinicOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT00540982 | Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction | completed | Phase 1 / Phase 2 | 47 | City of Hope Medical CenterOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT03884556 | TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers | completed | Phase 1 | 56 | Trishula Therapeutics, Inc.INDUSTRY | 1 | Jul 2, 2025 | clinicaltrials |
| NCT03781934 | A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations | completed | Phase 1 / Phase 2 | 53 | MedivirINDUSTRY | 4 | Jul 1, 2025 | clinicaltrials |
| NCT01226316 | Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules | completed | Phase 1 | 285 | AstraZenecaINDUSTRY | 10 | Jun 29, 2025 | clinicaltrials |
| NCT02159716 | CART-meso in Mesothelin Expressing Cancers | completed | Phase 1 | 19 | University of PennsylvaniaOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT03592888 | DC Vaccine in Pancreatic Cancer | completed | Phase 1 | 29 | University of PennsylvaniaOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT04400188 | A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 25 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 29, 2025 | clinicaltrials |
| NCT04608409 | Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer | completed | Phase 1 | 16 | Frederick R. Ueland, M.D.OTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT03081858 | Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer | completed | Phase 1 / Phase 2 | 15 | Lipac Oncology LLCINDUSTRY | 1 | Jun 27, 2025 | clinicaltrials |
| NCT03106415 | Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 23 | Mayo ClinicOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT03635164 | Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma | completed | Phase 1 | 21 | University of Colorado, DenverOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT03767335 | MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer(B-PRECISE-01) | completed | Phase 1 | 62 | Menarini GroupINDUSTRY | 6 | Jun 26, 2025 | clinicaltrials |
| NCT04963088 | Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT)(TALENT) | completed | Phase 1 / Phase 2 | 65 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT02191891 | Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 32 | Boehringer IngelheimINDUSTRY | 4 | Jun 25, 2025 | clinicaltrials |
| NCT02546167 | CART-BCMA Cells for Multiple Myeloma | completed | Phase 1 | 25 | University of PennsylvaniaOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT01995669 | Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 66 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT04525859 | Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma | completed | Phase 1 | 19 | Oncovir, Inc.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT00873275 | Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer | completed | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT02446964 | Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia | completed | Phase 1 | 31 | City of Hope Medical CenterOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT03900598 | A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 | 226 | Janssen Research & Development, LLCINDUSTRY | 12 | Jun 22, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jul 24, 2025source: clinicaltrials